McKee Amy E

SEC Form 4 insider trading activity

McKee Amy E has filed 7 SEC Form 4 filings (7 transaction rows) across 1 company, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: Sep 2, 2026.

On the most recent filing, McKee Amy E is listed as Director at BIOCRYST PHARMACEUTICALS INC. Inside the rolling window, McKee Amy E reported no open-market purchases and 1 open-market sale totaling $100K in BCRX.

Companies traded

Other insiders at BCRX

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$100K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
BCRXSale$100KMay 19SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has McKee Amy E made?

McKee Amy E has filed 7 SEC Form 4 filings (7 transaction rows) across 1 company since 2025.

Which companies does McKee Amy E trade?

McKee Amy E has filed SEC Form 4 disclosures for 1 company, including BCRX.

When was McKee Amy E's most recent SEC Form 4 filing?

McKee Amy E's most recent SEC Form 4 filing on Tracefour is dated Sep 2, 2026.

What is McKee Amy E's total buy and sell value in the current window?

Inside the rolling retention window, McKee Amy E bought $0 and sold $100K based on SEC Form 4 filings.

What was McKee Amy E's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 11,180 BCRX shares on 2026-05-18, worth $100K, per SEC Form 4 filings.